EU FIRMS WELCOME PROBE INTO TURKEY'S PHARMACEUTICALS MARKET.
The European Federation of Pharmaceutical Industries and Associations has welcomed a European Commission decision to start a formal examination of Turkey's legislation on trade in medicines. The European industry has long argued that trade barriers have inhibited its operations there. They have repeatedly alleged lack of transparency, discriminatory application of controls on pharmaceutical imports, sales and marketing, and discriminatory treatment in marketing approvals procedures, distribution channels, and the pricing and reimbursement regimes. And they say companies are faced with lack of protection for commercially sensitive data as part of the marketing approvals procedure.
In October 2003, EFPIA lodged a complaint under the Trade Barrier Regulation (Article 4 of Regulation 3286/94) to seek the removal of what it alleged were discriminatory trade practices that act as a barrier for European industry to operate in the Turkish market. In December, the Commission took the first step in legal action on the grounds cited.
According to EFPIA's Director-General, Brian Ager, "Numerous attempts have been made to engage with Turkish authorities directly or through the intervention of officials from EU Member States and the Commission. Unfortunately, no progress has been achieved so far". Meanwhile, he went on, "research-based pharmaceutical companies have invested in Turkey helping to ensure that Turkish patients have access to their innovative products, while contributing to the economic development of the country. Compliance with European and international commitments is important and will further encourage these investments". EFPIA says its complaint "is to achieve a fair and level playing field for all pharmaceutical companies operating in Turkey".
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||european union|
|Article Type:||Brief Article|
|Date:||Jan 10, 2004|
|Previous Article:||ACCOUNTANCY INDUSTRY WANTS STRONGER EU ENFORCEMENT BODY FOR IFRS.|
|Next Article:||INDUSTRIAL PRODUCER PRICES ROSE 0.2% IN NOVEMBER 2002.|